Somapacitan-beco

Limits on what this shows

• Key negative/null findings: Label characterizes the changes as intermittent and non-progressive rather than a sustained trajectory toward hyperphosphatemia.
• At-risk subgroups: Patients with pre-existing hyperphosphatemia or chronic kidney disease, where renal phosphate clearance is already impaired, and where the label separately notes somapacitan-beco exposure rises as eGFR falls.

Regulatory status

SOGROYA US PI, Section 6 (Adverse Reactions): "more SOGROYA treated patients shifted from normal baseline levels to elevated phosphate and creatine phosphokinase levels at the end of the trial compared to the placebo group (17.5% vs 4.9% and 9.2% vs 6.6%, respectively)." Section 5 states serum phosphorus and alkaline phosphatase "have increased after somatropin therapy, including SOGROYA," and that laboratory changes were "intermittent and non-progressive."

Population evidence

REAL 1, the pivotal phase 3 trial (Johannsson et al. 2020, J Clin Endocrinol Metab, PMID 32022863, DOI 10.1210/clinem/dgaa049): 301 randomized treatment-naive adults with GHD (120 somapacitan, 119 daily GH, 61 placebo), 34-week main period plus 52-week extension. The 17.5% vs 4.9% phosphate shift is drawn from this cohort as reported in the current label.

Mechanism

Named, shared with the GH-receptor class: GH/IGF-1 increases renal tubular phosphate reabsorption and bone turnover, raising serum phosphate. Not specific to the albumin-binding modification.

Counter-evidence held on record

No source located suggests somapacitan-beco lowers serum phosphate; direction is consistent with the whole GH-receptor class, including daily somatropin (this project's B002 dossier, also graded orange for the same reason). Excess-direction finding. No phosphate supplementation is ever indicated; monitor for hyperphosphatemia specifically in patients with renal impairment. This is the drug's own labeled pharmacology, not a nutrient deficiency.

Limits on what this shows

• Key negative/null findings: Label describes the effect as usually transient and dose-dependent, implying resolution with dose reduction rather than a fixed, cumulative loss.
• At-risk subgroups: Adults, especially those with pre-existing hypertension, heart failure, or other edema-prone states.

Regulatory status

SOGROYA US PI, Section 5: "clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent."

Population evidence

Label-level finding drawn from the pooled adult and pediatric SOGROYA clinical trial program (Section 6 adverse reaction tables list peripheral edema at 3.3% in adults with GHD).

Mechanism

Shared class mechanism (confirmed for daily somatropin in this project's B002 dossier via Hanukoglu et al. 2001, PMID 11358674): GH stimulates the renin-angiotensin-aldosterone axis and renal epithelial sodium channel activity, promoting sodium and secondary water reabsorption. Not independently re-verified for somapacitan-beco itself in a mechanistic study; the label's own adverse-reaction data is the drug-specific Tier A evidence used here.

Counter-evidence held on record

No source located suggests somapacitan-beco causes sodium loss; direction is consistently retention across the label. This is a retention/excess risk, not a depletion. Sodium supplementation is not indicated and could worsen fluid overload. Symptomatic retention should go to the prescriber for dose review, not to independent dietary sodium changes.

Limits on what this shows

• Key negative/null findings: Takahashi Y, Biller BMK, Fukuoka H, et al. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. Pituitary. 2023. PMID 36380045, DOI 10.1007/s11102-022-01283-3. Pooled analysis of REAL 1 (main plus extension), REAL 2, and REAL Japan (combined N in the several hundreds across treatment-naive and previously-treated adults): no new cases of diabetes mellitus in the somapacitan-beco group versus 2 (REAL 1) and 1 (REAL Japan) in the daily-GH groups; changes in fasting plasma glucose, HbA1c, fasting insulin, HOMA-IR, and HOMA-B were not statistically significant between somapacitan-beco and daily GH through 86 weeks.
• At-risk subgroups: Not established beyond the general GH-class insulin-sensitivity warning; the CGM study specifically excluded patients with diabetes, so the finding's relevance to a pre-diabetic or diabetic population is unconfirmed.

Regulatory status

SOGROYA US PI, Section 5: "treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes mellitus has been reported in patients taking somatropin," a class-level warning applied to the drug's own labeling.

Population evidence

Taguchi T, Kimura K, Tsuji S, et al. Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring. J Endocr Soc. 2025;10(1):bvaf193. Prospective, single-arm, single-center study, 17 adults with GHD without diabetes, each measured on both daily GH and weekly somapacitan-beco. Mean sensor glucose was significantly higher on somapacitan-beco (105.0 ± 10.7 mg/dL vs 98.7 ± 10.1 mg/dL, P=.0046), with a biphasic weekly pattern peaking day 2 and troughing day 4. Time above 140 mg/dL rose (9.0% vs 5.6%, P=.0038) and time above 180 mg/dL rose (1.17% vs 0.66%, P=.0024). Fasting glucose (97.2 vs 97.2 mg/dL, P=.88), HbA1c (5.69% vs 5.70%, P=.66), and HOMA-IR (2.58 vs 2.08, P=.17) did not differ significantly.

Mechanism

Named: the weekly, supraphysiologic-then-trough IGF-1/GH exposure pattern inherent to the albumin-binding, once-weekly formulation (versus daily GH's steadier exposure) plausibly drives a real but small day-to-day glycemic swing, distinct from the underlying GH-class insulin-sensitivity mechanism itself.

Counter-evidence held on record

The Takahashi 2023 pooled analysis is itself substantial counter-evidence against a clinically meaningful effect: several hundred patients across three trials up to 86 weeks showed no significant HbA1c or HOMA-IR difference and fewer new diabetes cases with somapacitan-beco than with daily GH. The Taguchi CGM study is small (n=17), single-center, and non-randomized (each patient served as their own comparison across separate treatment periods), which bounds how far its real, statistically significant CGM findings should be generalized. This reflects the drug's own labeled pharmacologic effect on insulin sensitivity and its dosing-interval-driven exposure pattern, not a nutrient deficiency. No dietary or supplement action is indicated; routine glucose monitoring per the label's existing recommendation is the appropriate response.

Limits on what this shows

• Key negative/null findings: No somapacitan-specific serum calcium data (elevated or depressed) was located either way.
• At-risk subgroups: By class analogy: patients with a personal history of hypercalciuria or nephrolithiasis, and pediatric long-term use.

Regulatory status

SOGROYA US PI, Section 5: "serum levels of parathyroid hormone may increase with somatropin treatment," language shared with the rest of the H01AC class and applied to SOGROYA's own label without a somapacitan-specific quantified figure.

Population evidence

No somapacitan-specific calcium or calciuria study was found in this review (PubMed search-listing pages for somapacitan combined with calcium returned zero drug-specific hits; see Ungraded section and Sources). Class-level evidence for daily somatropin (this project's B002 dossier) found increased urinary calcium excretion with a compensatory PTH rise and stable serum calcium, drawing on the somatropin FDA label and Hanukoglu et al. 2001.

Mechanism

Named at the class level: GH/IGF-1 increases bone turnover and renal tubular calcium filtration/excretion, with the parathyroid axis defending serum calcium via a secondary PTH rise. Not independently confirmed for somapacitan-beco's specific weekly exposure pattern.

Counter-evidence held on record

None found in either direction specific to somapacitan-beco. Not a basis for calcium or vitamin D supplementation. Monitoring calcium, PTH, and renal calcium handling is a prescriber decision; no dose is recommended here.

Limits on what this shows

• Key negative/null findings: The same study found increased adiposity indices with somapacitan-beco, a finding that cuts against a simple "somapacitan-beco is metabolically favorable" reading and is recorded here as a caution against overinterpreting the HDL result in isolation.
• At-risk subgroups: None identified; self-selected, non-randomized design limits subgroup inference.

Regulatory status

Not addressed in the FDA label.

Population evidence

Oi-Yo Y, Urai S, Yamamoto M, et al. Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2026;111(9):e2096-e2107. DOI 10.1210/clinem/dgag153. Prospective, observational, non-randomized comparative study, 52 weeks, 57 adults with GHD, self-selected to switch to weekly somapacitan-beco or continue daily somatropin at a single center. Somapacitan-beco was associated with improved HDL cholesterol relative to continued daily somatropin; the same study found somapacitan-beco associated with increased adiposity indices and a smaller IGF-1 SDS increase than daily GH, with no significant between-group difference in the lean-mass primary endpoint.

Mechanism

Not established in the source; not mechanistically explained.

Counter-evidence held on record

The same study's adiposity-index finding runs counter to a straightforward protective reading; this is disclosed rather than omitted. Single small non-randomized study. Not a basis for any dietary or supplement claim; not a nutrient finding at all, but a lipid-marker observation carried here because it is drug-specific, real, and directly relevant to the GH-axis metabolic profile.

Limits on what this shows

• Key negative/null findings: The two largest, most recent class-level studies (combined n=208 treated children, daily somatropin) found no change in 25(OH)D.
• At-risk subgroups: GHD patients generally have a high baseline prevalence of vitamin D insufficiency independent of which GH-receptor agonist is used, reflecting the underlying condition rather than either drug's pharmacology (Hard Rule 6).

Regulatory status

Not addressed in the FDA label.

Population evidence

No somapacitan-specific source exists (confirmed zero-result PubMed search-listing query combining somapacitan with vitamin D; see Sources). Class-level Tier C evidence, drug not in cohort, carried from this project's B002 somatropin dossier: Durá-Travé et al. (2020), PMID 32215862, n=98 GHD children vs 247 controls, 24-month follow-up, found daily GH therapy "didn't modify vitamin D levels"; Durá-Travé and Gallinas-Victoriano (2022), Children (Basel), PMID 35626902, n=110 vs 377 controls, 48-month follow-up, found calcidiol unchanged (P=.501); Hamza et al. (2018), DOI 10.1136/jim-2017-000618, n=50 vs 50, found 25(OH)D rose after 1 year of GH therapy (P<.001), a reverse-direction signal in tension with the two larger null studies.

Mechanism

Named at the class level: GH/IGF-1 stimulates renal 1-alpha-hydroxylase, increasing conversion of 25(OH)D to active 1,25(OH)2D, an activation effect rather than a depletion of vitamin D stores. Applies mechanistically to any effective GH-receptor agonist, including somapacitan-beco, though not directly tested for it.

Counter-evidence held on record

The two largest class-level studies are themselves the counter-evidence to any depletion claim, for a different drug than the one reviewed here. Reverse-direction or null class-level finding, not a depletion signal, and not confirmed for somapacitan-beco specifically. Not a basis for withholding vitamin D monitoring in GHD patients generally, since the high baseline deficiency prevalence in this population is real but not drug-caused.

Limits on what this shows

• Key negative/null findings: Richards and Marshall's null finding is itself the key counter-evidence within the class; both primary sources predate or coincide with the pituitary-to-recombinant GH transition and neither used somapacitan-beco or its once-weekly exposure pattern.
• At-risk subgroups: Cannot be determined from directly conflicting class-level evidence.

Regulatory status

Not addressed in the FDA label.

Population evidence

No somapacitan-specific source exists (confirmed zero-result PubMed search-listing query for somapacitan combined with zinc/trace element; see Sources). Class-level Tier C evidence, drug not in cohort, carried from this project's B002 somatropin dossier: Richards and Marshall (1981/1983), n=8 children with GHD given pituitary-derived GH, found no significant zinc change in serum, urine, or hair; Aihara et al. (1985), PMID 4032177, found plasma zinc decreased in GHD patients after hGH treatment, correlated with serum hGH level, pointing to GH-driven renal zinc wasting.

Mechanism

Named in one direction only, at the class level: GH activity promoting urinary zinc excretion, not replicated in the smaller comparison cohort. Not tested for somapacitan-beco.

Counter-evidence held on record

No source located reports a zinc effect from any currently marketed recombinant GH-receptor agonist, including somapacitan-beco. Mechanistically plausible in one direction at the class level but directly contradicted by another primary study in a comparable population, for a different drug. Not a basis for zinc supplementation without direct measurement in an individual patient.

Limits on what this shows

• Why no grade is withheld: Per Step 7, ungraded requires both no Tier B/C evidence AND no circulating claim to rebut. Somapacitan-beco and daily somatropin activate the identical growth hormone receptor and downstream IGF-1 axis, differing only in the albumin-binding modification that extends the half-life for weekly dosing; that shared receptor pharmacology makes the somatropin literature genuine, if weak, Tier C class-level evidence for somapacitan-beco, which is sufficient to clear the yellow bar in every case here. This is disclosed in each entry, with the class member's identity and the fact that somapacitan-beco was not in that cohort stated explicitly, per the cohort test.

Research channels tried and outcome

PubMed search-listing pages (https://pubmed.ncbi.nlm.nih.gov/?term=...) under multiple phrasings for somapacitan combined with vitamin D, calcium, microbiome, mitochondria, oxidative stress, copper, zinc, selenium, trace element, gut microbiota, mitochondrial, hemoglobin, hematocrit, anemia, and iron: all returned confirmed zero-result pages (meta-log_resultcount: 0) except where the word "hemoglobin" matched unrelated HbA1c glucose-metabolism studies, which is itself a genuine finding of absence, not a blocked search. General web search located several real somapacitan-specific clinical trial and pharmacology sources (used throughout the orange and select yellow entries above) but nothing touching the seven required categories directly. Europe PMC REST API (www.ebi.ac.uk/europepmc) was attempted twice and returned a timeout, then would likely have 429'd; Crossref API (api.crossref.org) returned HTTP 429 on the one attempt made; Semantic Scholar API returned HTTP 429 on an earlier attempt in this session. Direct PubMed article abstract pages (as opposed to search-listing pages) and several PMC full-text pages returned bot-verification or reCAPTCHA challenge pages rather than content on repeated attempts and were not used as sources; where a promising title was found this way (for example the thyroid-switching pilot study, PMID 42335808, and PMC11453290) it is listed in Sources as located but not opened, and no claim from it is asserted anywhere in this dossier.

Genuine gap, not tooling-limited

The PubMed search-listing channel itself worked throughout this review (it returned real, confirmed zero-result pages, and it separately returned real results for other somapacitan queries such as glucose metabolism and bone age), so the zero results for the seven required categories reflect an actual absence of published somapacitan-specific literature at this drug's low prescribing volume and 2020 approval date, not a blocked or rate-limited tool. The Europe PMC, Crossref, and Semantic Scholar blocks are disclosed above as a genuine tooling limitation encountered in this review, but they are not the reason any category ended up ungraded, since none did; a future revision with clean access to those three channels should re-attempt them before assuming this disclosure is stale.